$761 Million is the total value of Broadfin Capital, LLC's 50 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $174,944,000 | – | 700,000 | +100.0% | 23.00% | – |
| NVRO | New | NEVRO CORP | $28,950,000 | – | 744,415 | +100.0% | 3.81% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $13,875,000 | – | 1,877,502 | +100.0% | 1.82% | – |
| NVRO | New | NEVRO CORPcall | $11,667,000 | – | 300,000 | +100.0% | 1.53% | – |
| INCY | New | INCYTE CORP | $11,656,000 | – | 183,300 | +100.0% | 1.53% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $9,889,000 | – | 240,909 | +100.0% | 1.30% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $5,715,000 | – | 58,700 | +100.0% | 0.75% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $4,782,000 | – | 129,300 | +100.0% | 0.63% | – |
| OPTN | New | OPTINOSE INC | $4,406,000 | – | 710,600 | +100.0% | 0.58% | – |
| NEOS | New | NEOS THERAPEUTICS INC | $4,321,000 | – | 2,618,819 | +100.0% | 0.57% | – |
| OSMT | New | OSMOTICA PHARMACEUTICALS PLC | $4,096,000 | – | 528,571 | +100.0% | 0.54% | – |
| DOVA | New | DOVA PHARMACEUTICALS INC | $2,667,000 | – | 351,800 | +100.0% | 0.35% | – |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $1,456,000 | – | 143,300 | +100.0% | 0.19% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.